Mon, 21 May 2018 07:33:00 +0100
MaxCyte pre-clinical data shows correction of sickle cell disease mutation
Pre-clinical data presented Friday (May 18) at an industry assessed the use of non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder
Thu, 17 May 2018 08:02:00 +0100
Horizon Discovery Group bids farewell to Abcam founder who exits board following failed bid approach
Jonathan Milner's exit ends a decade-long association with Horizon and he wished the team there well, adding he felt "enormously privileged to have been a part of this exciting journey"
Wed, 16 May 2018 14:20:00 +0100
Warren Buffett's Berkshire Hathaway loads up on Apple, Teva Pharmaceuticals, Monsanto
Berkshire Hathaway still hasn’t really started unwinding its massive Wells Fargo investment in the wake of the bank's scandals
Tue, 15 May 2018 10:54:00 +0100
Genedrive to sell contract research and pharmacogenomics divisions for up to
Mon, 14 May 2018 07:36:00 +0100
IXICO bags a
Fri, 11 May 2018 07:20:00 +0100
Faron Pharmaceuticals gains some early understanding of phase III trial data
The company is taking a closer look at the results from its INTEREST study
Thu, 10 May 2018 13:33:00 +0100
Sareum Holdings pleased as Sierra Oncology advances cancer drug trial
"We are very pleased with the progress that Sierra Oncology has made across its clinical trials and future plans with SRA737,” said Dr Tim Mitchell
Thu, 10 May 2018 07:29:00 +0100
IXICO sees contracts' value increased by around
Wed, 09 May 2018 13:23:00 +0100
Flying Brands' imaging subsidiary inks Athens cancer hospital deal
The ground-breaking imaging software will be used by the General Anti-Cancer and Oncological Hospital
Tue, 08 May 2018 15:50:00 +0100
Shire’s Japanese takeover confirmed, but what does it say about London’s blue-chips?
Deal capital is clearly sloshing around blue-chip boardrooms, but, are we seeing a run of takeovers near the top of the market?
Tue, 08 May 2018 07:32:00 +0100
Faron Pharma assesses options after phase III disappointment
CEO, Dr Markku Jalkanen, said he and his team was "incredibly disappointed and surprised" by the results, which were at odds with data garnered from an earlier trial
Tue, 01 May 2018 08:00:00 +0100
Avacta on track to deliver pre-clinical milestones this year
The company is making progress with its lead immuno-oncology programmes
Mon, 23 Apr 2018 16:45:00 +0100
Woodford-backed Prothena collapses as it scraps development of lead drug after mid-stage trial failure
NEOD001 was being developed to treat a rare disease called AL amyloidosis, but it missed both its primary and secondary endpoints in a Phase IIb trial and Prothena has decided to scrap its development altogether
Fri, 20 Apr 2018 09:39:00 +0100
The high holiday for smoking pot: 4/20 festivities planned worldwide
At 4:20pm, thousands around the world will participate in a synchronized smoke-off.
Fri, 16 Feb 2018 16:00:00 +0000
Faron Pharmaceuticals raises
Mon, 05 Feb 2018 07:39:00 +0000
Faron establishes second Traumakine manufacturing site as it prepares for commercialisation
The read-out from the recently-completed INTEREST study is due later this half and Faron is getting its house in order should the data come back positive
Thu, 01 Feb 2018 15:00:00 +0000
Faron extends patent protection for Clevegen cancer immunotherapy
"The grant of this patent serves to protect the innovative mechanism underlying Clevegen, which will be important in realising the potential our second wholly-owned product promises"
Mon, 29 Jan 2018 12:15:00 +0000
Faron Pharmaceuticals drug receives fast-track designation from US regulator
This accelerated review is designed to get drugs to areas of unmet medical need
Wed, 24 Jan 2018 16:07:00 +0000
Faron Pharmaceuticals makes more headway with the US regulator
Chief executive Dr Markku Jalkanen said he was pleased with the latest approval from the Food & Drug Administration
Wed, 24 Jan 2018 14:41:00 +0000
Faron Pharma: Share price tracks progress of flagship drug
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
Tue, 19 Dec 2017 07:32:00 +0000
Faron Pharmaceuticals receives clinical trial green light in second indication for lead drug
Traumakine is being tested for safety and efficacy in patients with multi-organ failure - this is a potential second indication for the drug
Mon, 11 Dec 2017 09:17:00 +0000
Faron Pharmaceuticals completes recruitment for phase III trials of its ARDS treatment
300 patients have now been recruited across Europe for the trial which is looking at whether Traumakine can reduce all-cause mortality in acute respiratory distress syndrome sufferers
Fri, 01 Dec 2017 07:54:00 +0000
Faron Pharmaceuticals hires chief commercial officer ahead of drug launch
Dr Juhana Heinonen will join the business in January from AstraZeneca
Thu, 05 Oct 2017 08:24:00 +0100
Mon, 02 Oct 2017 14:00:00 +0100
Faron Pharmaceuticals' lead drug gets significant vote of confidence from UK regulator
The Medicines and Healthcare Products Regulatory Agency has given Faron drug,Traumakine, a Promising Innovative Medicines designation
Wed, 06 Sep 2017 14:50:00 +0100
Faron Pharma primed for a pivotal period in its development
The company is more advanced than many of its AIM compatriots, with a drug undergoing Phase III clinical trials
Mon, 04 Sep 2017 10:58:00 +0100
Faron Pharma gets a boost as FDA says can use outside US trial data for Traumakine license application
Dr Markku Jalkanen, Faron's CEO, said: "This important feedback potentially speeds up the regulatory approval process in the US and brings us one step closer to delivering Traumakine to patients in the world's largest pharmaceutical market“
Fri, 04 Aug 2017 07:27:00 +0100
Faron Pharma to provide drug compassionate use of drug; data monitors green light study as it moves into its final few months
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Mon, 08 May 2017 14:31:00 +0100
Faron Pharmacueticals' Traumakine study making good progress
The independent data monitoring committee has now reviewed the trial data four times
Wed, 19 Apr 2017 08:03:00 +0100
Drug developer Faron Pharmaceuticals to appoint two industry heavyweights to the board
Dr Gregory Brown and John Poulos bring with them a breadth and depth of industry experience
Wed, 21 Feb 2018 12:14:00 +0000
A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine results in Q2
Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (), caught up with Proactive following their
Wed, 06 Sep 2017 12:54:00 +0100
Faron Pharmaceuticals boss upbeat as Phase III trial enters critical period
Dr Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd () tells Proactive's Andrew Scott they're entering an exciting period for the company with recruitment for their Phase III trial for its lead drug set for completion later this year.
A positive readout for Traumakine, which is used to treat acute respiratory distress syndrome caused by pneumonia, would pave the way for its launch in Europe and the US.
Clevegen, Faron’s cancer immunotherapy, is set to undergo preclinical toxicity studies.
Tue, 18 Apr 2017 13:22:00 +0100
Faron Pharmaceuticals' Markku Jalkanen 'excited' to be advancing Clevegen
Markku Jalkanen, chief executive of clinical stage biopharma group () tells Proactive he's hugely excited to be teaming up with the University of Birmingham as they look to advance their potential cancer immunotherapy, Clevegen.
Wed, 29 Mar 2017 15:59:00 +0100
'This year will give us the results we've been waiting for', says Faron pharmaceuticals boss
Faron Pharmaceuticals Ltd () CEO Dr Markku Jalkanen caught up with Proactive to run through the company's 2016 results and outlook for the year ahead.
Traumakine, used to treat acute respiratory distress syndrome, is undergoing a phase III clinical trial with results expected in the second half.
Traumakine is now being developed for a second indication, a condition called rupture of abdominal aorta aneurysm.
Thu, 09 Feb 2017 11:36:00 +0000
Faron Pharmaceuticals to build on success of 'extremely exciting' 2016
Dr Markku Jalkanen, chief executive,
Thu, 02 Feb 2017 12:54:00 +0000
Rainmaker Resources has an early stage project in hot commodity lithium
Chris Healey, chief executive at Toronto-listed
Mon, 31 Oct 2016 13:23:00 +0000
Faron Pharmaceuticals boss says patent protection is very significant step
() chief executive Dr Markku Jalkanen says securing patent protection is a very significant step for the company.
“This is the very first ever granted claims to protect intravenous use of interferon-beta,” he highlighted in a Proactive Investors interview.
The drug developer now intends to transpose the patent protections in Finland across some 150 countries covered by international co-operation arrangements, and it will separately file into the US patents office.
“So this was the very initial filing and we are really happy that we got the claims accepted and it is a very significant step for us.”
Wed, 28 Sep 2016 11:01:00 +0100
Faron Pharmaceuticals Oy’s options widen after fund-raising
Demand for shares in ’s () was strong when the company tapped the City last week for
Tue, 06 Sep 2016 15:25:00 +0100
Faron Pharmaceuticals Oy boss pleased with healthier than expected cash balance
() ended the first half of 2016 with more cash than it had anticipated.
Research & development (R&D) expenses more than doubled, but the combination of higher than anticipated income, in the form of both revenue and grant income, and lower operating costs meant the company experienced only a modest cash outflow over the reporting period.
Chief executive Dr Markku Jalkanen told Proactive revenue comprised mostly of a ˆ750,000 signing fee from Pharmbio and a ˆ356,500 pre-payment relating to IFB-beta production.
The group also received ˆ968,000 from the European Union from its FP7 Traumakine grant.
The company had a cash balance of ˆ8.9mln at the end of June, it revealed in its results for the first half of the year.
Wed, 29 Jun 2016 12:46:00 +0100
Faron Pharmaceuticals drug has ‘tremendous potential’ following Korea deal, says CEO
Finland-based clinical stage drug discovery company Faron Pharmaceuticals () says there is “tremendous expansion potential” following the latest licensing deal with a Korean pharmaceuticals firm.
The group’s treatment for Acute Respiratory Distress Syndrome, Traumakine is on track to be the very first pharmacological treatment for this serious condition, explains chief executive Markku Jalkanen.
“The disease is very deadly, death usually occurs in 30-45% of patients,” says Jalkanen. The treatment is already in phase III trials in Europe and licences have been picked up by three companies in Asia, including the deal with Korean firm Pharmbio.
Speaking of the potential licences in its three major areas, including immunotherapy, chronic infection and vaccination, Jalkanen says that “if successful they will last for twenty years from now, so it’s a long term business opportunity for anyone utilising these technologies.”
Tue, 19 Apr 2016 11:03:00 +0100
Faron Pharma chief hopes for global patent protection for Clevegen
Markku Jalkanen, chief executive of
Wed, 03 Feb 2016 09:02:00 +0000
Faron Pharmaceuticals boss talks Traumakine and recent listing on AIM
Finland-based () has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage with its most promising product – Traumakine – a late stage product for acute respiratory distress syndrome.
Speaking to Proactive, chief executive Markku Jalkanen said the treatment, currently in Phase III trials in Europe, would be the first non-mechanical treatment for ARDS in the world.
The firm listed on AIM in November raising
view page: 8